Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.

Abstract

Studies of human immunodeficiency virus (HIV) vaccines in animal models suggest that it is difficult to induce complete protection from infection (sterilizing immunity) but that it is possible to reduce the viral load and to slow or prevent disease progression following infection. We have developed an age-structured epidemiological model of the effects of a disease-modifying HIV vaccine that incorporates the intrahost dynamics of infection, a transmission rate and host mortality that depend on the viral load, the possible evolution and transmission of vaccine escape mutant viruses, a finite duration of vaccine protection, and possible changes in sexual behavior. Using this model, we investigated the long-term outcome of a disease-modifying vaccine and utilized uncertainty analysis to quantify the effects of our lack of precise knowledge of various parameters. Our results suggest that the extent of viral load reduction in vaccinated infected individuals (compared to unvaccinated individuals) is the key predictor of vaccine efficacy. Reductions in viral load of about 1 log(10) copies ml(-1) would be sufficient to significantly reduce HIV-associated mortality in the first 20 years after the introduction of vaccination. Changes in sexual risk behavior also had a strong impact on the epidemic outcome. The impact of vaccination is dependent on the population in which it is used, with disease-modifying vaccines predicted to have the most impact in areas of low prevalence and rapid epidemic growth. Surprisingly, the extent to which vaccination alters disease progression, the rate of generation of escape mutants, and the transmission of escape mutants are predicted to have only a weak impact on the epidemic outcome over the first 25 years after the introduction of a vaccine.

• Authors: Miles P Davenport, Ruy M Ribeiro, Dennis L Chao, Alan S Perelson
• Journal: Journal of virology (J Virol) Vol. 78 Issue 20 Pg. 11340-51 (Oct 2004) ISSN: 0022-538X [Print] United States
• PMID: 15452255 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• AIDS Vaccines

Topics

• AIDS Vaccines (administration & dosage, immunology)
• Disease Outbreaks
• Disease Progression
• HIV (genetics, physiology)
• HIV Infections (mortality, prevention & control, transmission, virology)
• Humans
• Incidence
• Models, Biological
• Predictive Value of Tests
• Time Factors
• Vaccination
• Viral Load